Advertisement

Drugs in R & D

, Volume 8, Issue 6, pp 400–402 | Cite as

MN 001

KCA 757, KCA-757, MN-001
Adis R&D Profile
  • 25 Downloads

Keywords

Interstitial Cystitis Obstructive Airway Disease Moderate Asthma Late Asthmatic Response Methacholine Challenge Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Technology Vision Group LLC. BioPartnering North America. 4th Annual BioPartnering North America: 5 Feb 2006Google Scholar
  2. 2.
    MediciNova Inc. MediciNova Announces the Completion of Enrollment of a Phase II Study for Its Novel, Oral Asthma Treatment. Media Release: 7 Sep 2005. Available from URL: http://www.medicinova.com Google Scholar
  3. 3.
    MediciNova Inc. MediciNova Announces the Initiation of the Phase III Clinical Program for MN-001, a Novel Oral Treatment for Bronchial Asthma. Media Release: 16 Nov 2006. Available from URL: http://www.medicinova.com Google Scholar
  4. 4.
    Busse WW, Nelson HS, Korenblat PE, et al. Effects of MN-001 in patients with mild-to-moderate asthma in a randomized, double-blind and placebo-controlled phase II study. Journal of Allergy and Clinical Immunology 119 (Suppl.): 5, No. 1, Jan 2007CrossRefGoogle Scholar
  5. 5.
    MediciNova Inc. MediciNova Announces Positive Clinical Results With MN-001 in a Phase II Asthma Trial. Media Release: 14 Dec 2005. Available from URL: http://www.medicinova.com Google Scholar
  6. 6.
    MediciNova Inc. MediciNova Reports 2006 Financial Results Six Compounds Advancing Through Clinical Trials. Media Release: 15 Feb 2007. Available from URL: http://www.medicinova.com Google Scholar
  7. 7.
    MediciNova Inc. MediciNova Announces Notice of Allowance for Two Key Patent Applications for MN-001. Media Release: 4 Jan 2006. Available from URL: http://www.medicinova.com Google Scholar
  8. 8.
    Locke KW. Phase I study of MN-001, an oral anti-inflammatory agent for the treatment of asthma. Journal of Allergy and Clinical Immunology 115 (Suppl.): 151 (plus poster), abstr. 603, No. 2, Feb 2005CrossRefGoogle Scholar
  9. 9.
    Uno T, Toru T, Namiki H. Pharmacological profile of KCA-757, a novel anti-asthmatic drug. 3. Pharmacological activities of KCA-907, a major metabolite of KCA-757. XV International Congress of Allergology and Clinical Immunology (Suppl. 2): 281, 1994Google Scholar
  10. 10.
    Ohashi M, Uno T, Namiki H. Pharmacological profile of KCA-757, a novel anti-asthmatic drug. 2. Effects on bronchial hyperreactivity and late asthmatic response in guinea pigs. XV International Congress of Allergology and Clinical Immunology (Suppl. 2): 281, 1994Google Scholar
  11. 11.
    Ohashi M, Uno T, Kishi T. Pharmacological profile of KCA-757, a novel anti-asthmatic drug. 1. Effects on LTD4-and antigen-induced bronchoconstriction in guinea pigs. XV International Congress of Allergology and Clinical Immunology (Suppl. 2): 281, 1994Google Scholar
  12. 12.
    MediciNova Inc. MediciNova Announces Results From a Phase II/III Interstitial Cystitis Trial With MN-001. Media Release: 16 Jan 2007. Available from URL: http://www.medicinova.com Google Scholar

Copyright information

© Adis Data Information BV 2007

Personalised recommendations